Ginkgo Bioworks (DNA) Fundamental Analysis: Revenue, Earnings & Valuation

5.64 / 10

Netural

Fundamentally, DNA rates neutral (5.6/10). Strengths include PB‑ROE, cash‑to‑market and inventory turnover; weaknesses are asset‑to‑market, fixed‑asset turnover and a –25% YoY revenue decline. Gross margin underperforms, while cost‑of‑sales is moderate, suggesting guarded health.

Analysis Checks(7/10)

Revenue-MV

Value-0.84

Score3/3

Weight30.45%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value-25.06

Score3/3

Weight3.76%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight19.29%

1M Return6.74%

Gross profit margin (%)

Value72.39

Score0/3

Weight-14.12%

1M Return-7.24%

PB-ROE

Value-0.64

Score2/3

Weight18.26%

1M Return6.97%

Income tax / Total profit (%)

Value0.27

Score2/3

Weight2.58%

1M Return1.04%

Fixed assets turnover ratio

Value0.30

Score1/3

Weight-2.69%

1M Return-1.24%

Cost of sales ratio (%)

Value27.61

Score2/3

Weight-9.27%

1M Return-4.42%

Asset-MV

Value-0.55

Score1/3

Weight34.61%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight17.14%

1M Return5.94%

Is DNA undervalued or overvalued?

DNA scores 5.64/10 on fundamentals and holds a Fair valuation at present. Backed by its -51.08% ROE, -183.81% net margin, -1.21 P/E ratio, 0.75 P/B ratio, and 46.49% earnings growth, these metrics solidify its Netural investment rating.